By OPEN MINDS Circle
In the first six months after starting addiction disorder treatment using the Pear Therapeutics reSET prescription digital therapeutic (PDT) device, people had a $3,591 reduction in per-person costs, compared to the six-month period before they started treatment. In a six-month study that included 101 adults treated with reSET, their hospital encounters were 50% lower. The number of inpatient stays was 56% lower, the number needing partial hospitalization dropped by 57%, and emergency department visits were 45% lower.
The reSET PDT is a software application intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for people 18 years of age and older, who are currently enrolled in outpatient addiction treatment under the supervision of a clinical professional. reSET is indicated as a 12-week (90 day) prescription-only treatment for consumers with addiction disorder, but who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse. reSET is intended increase the consumer’s abstinence level and increase retention in an outpatient treatment program.
The study evaluated real-world insurance claims from 101 adult patients with SUD treated with reSET. The comparison focused on the six months after initiation of reSET, and compared claims and utilization during the six months to their claims six months prior to starting treatment. The median age of the group was 37 years. About 54.5% were covered by Medicaid.
|
reSET Cohort Pre/Post Analysis Of Hospital Utilization Over Six Months (for 101 participants) | ||
|
Utilization Type | Six Months Before Treatment |
Six Months After Starting Treatment |
| Unique Hospital Encounters |
46 |
31 |
| Inpatient Stays |
22 |
12 |
| Partial Hospitalizations |
9 |
6 |
| Emergency Department Visits, Not Admitted |
35 |
22 |
These findings were reported in “Real-World Reductions In Healthcare Resource Utilization Over 6 Months In Patients With Substance Use Disorders Treated With A Prescription Digital Therapeutic” by Neel Shah, BPharm, Ph.D.; Fulton F. Velez, M.D., MS, MBA; Samuel Colman, MS; Laura Kauffman MS; and colleagues. The researchers conducted a retrospective analysis of HealthVerity PrivateSource20 data. They compared the six-month incidence of all-cause hospital facility encounters and clinical services used by consumers treated with reSET. The analysis compared costs and utilization for the six months before starting treatment with reSET and the six months after starting reSET. About 38% of the 101 participants were covered by commercial insurance, 55% were covered by Medicaid, 3% were covered by Medicare Advantage, and for 5% the payer was unknown.
Pear Therapeutics develops and markets PDTs for multiple therapeutic areas. Three of its PDTs have been authorized by the U.S. Food and Drug Administration (FDA) for commercial use; they are reSET®, reSET-O® for opioid addiction, and Somryst® for the treatment of chronic insomnia. The PDTs are designed to engage consumers in treatment and provide tracking tools for clinical professionals. Its PDTs are designed to collect real world data for use by prescribing clinical professionals and for population health management by payers and health systems.
For more information, contact: Meara Murphy, Senior Director, Corporate Communications, Pear Therapeutics, 200 State Street, Boston, Massachusetts 02109; Email: meara.murphy@peartherapeutics.com; Website: https://peartherapeutics.com/.